

QIBA CT Volumetry Biomarker Ctte (BC) Call

6 February 2017 at 11 AM CT

Draft Call Summary

In attendance:			RSNA:
Jenifer Siegelman, MD, MPH (Co-Chair)	Ritu Gill, MD, MPH	Kevin O'Donnell, MASc	Joe Koudelik
Maria Athelougou, PhD	Lubomir Hadjiiski, PhD	Nicholas Petrick, PhD	Julie Lisiecki
Rick Avila, MS	Rudresh Jarecha, MBBS	Uma Ranjan, PhD	
Andrew Buckler, MS	Claudia Kirsch, MD	Marthony Robins, PhD	
Heang-Ping Chan, PhD	Yongguang Liang, PhD	Na Sun, PhD	
Charles Fenimore, PhD	James Mulshine, MD	Ying Tang, PhD	
Marios Gavrielides, PhD	Nancy Obuchowski, PhD		

Review prior call summary: January 30th summary approved as submitted

Profile Checklist Review – Section 4 continued (Mr. O'Donnell)

- Discussion continued regarding whether or not modification and consistency of kVp is important
- Without consistency, there is a potential image edge effect when there is a time delay between scans
- kVp must be consistent with the baseline noise parameter and resolution parameter
- It was decided to leave kVp as is and require that it be consistent with the baseline measurement, if available
- The current boundary on image noise criteria may act as a kVp check for the Profile
- It was noted that there is a more significant effect when contrast is in use but prescriptive use was not necessary
- Sites will most likely use the baseline study and examine the header to find the kVp value

Assessment Procedure – Section 4.4

- Results will soon be available from Duke, Rush, and Brigham & Women's
- It is important to label the RIDER data set as *curated*
 - The curated dataset contains a zip file with DICOM images and a spreadsheet which characterizes lesions and provides space for responses
 - A spreadsheet is available for feasibility testers to record their data
- An issue occurred for Dr. Gill when trying to download the BETA software(CT 233) from Duke
 - Drs. Gill and Robins to confer offline to resolve this issue with the BETA analysis software
 - The ABM Revisions Committee indicated that the full version of the CT 233 software should be available by end of March
- Dr. Fenimore also intends test the CT 233 software to check for reasonable levels of agreement

Checklist

- Mr. O'Donnell to provide the checklist to Drs. Gill and Liang in Word
- Additional updates may be made after all of the feasibility testing results have been reviewed

Lungman Phantom Data

- Dr. Petrick indicated that posting the lungman phantom data is acceptable, as it is publicly available
 - Dr. Petrick intends to follow up with Dr. Erickson on 2/8 to discuss next steps for posting
- Once the data is posted, Dr. Siegelman and Mr. O'Donnell volunteered to test everything from a user perspective
- Dr. Siegelman asked that Drs. Goldmacher and Samei be apprised of updates: gregory.goldmacher@merck.com; ehsan.samei@duke.edu

Follow up items:

- QIDW datasets – Determine how streamlined the datasets should be
- Determine whether users should be directed to read-only pages for Profile required items and whether registration should be required for more in-depth analysis

Action items:

- Feasibility testing participants will report back to the group with their progress on the 2/20 WebEx call
- A dataset from Dr. Petrick for the Lungman phantom data is still needed for the QIDW
- Link testing for the QIDW will be needed
- Additional spreadsheets for a regression module as well as for the coordinates for the RIDER tumors are being compiled by Mr. Tervé

Next Calls:

Monday, February 13, 2017 at 11 am CT – (CT Coordinating Committee in place of BC call)

Monday, February 20, 2017 at 11 am CT – (Biomarker Committee)